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Abstract Sphingosine kinase (SK) catalyses the formation of
sphingosine 1-phosphate, a lipid second messenger that has been
implicated in mediating such fundamental biological processes as
cell growth and survival. Very little is currently known regarding
the structure or mechanisms of catalysis and activation of SK.
Here we have tested the functional importance of Gly113, a highly
conserved residue of human sphingosine kinase 1 (hSK), by site-
directed mutagenesis. Surprisingly, a Gly113CAla substitution
generated a mutant that had 1.7-fold greater catalytic activity
than wild-type hSK (hSKWT). Our data suggests that the
Gly113CAla mutation increases catalytic efficiency of hSK,
probably by inducing a conformational change that increases the
efficiency of phosphoryl transfer. Interestingly, hSKG113A
activity could be stimulated in HEK293T cells by cell agonists
to a comparable extent to hSKWT. ß 2001 Published by Else-
vier Science B.V. on behalf of the Federation of European Bio-
chemical Societies.
Key words: Sphingosine kinase; Enzyme catalysis ;
Sphingosine 1-phosphate; Lipid kinase
1. Introduction
Sphingosine kinase (SK) catalyses the formation of sphin-
gosine 1-phosphate (S1P), a lipid second messenger that ap-
pears to be involved in mediating such diverse and fundamen-
tal biological processes as cell growth and survival, as well as
calcium mobilisation, and adhesion molecule expression [1^4].
Cultured mammalian cells, in the absence of stimulating fac-
tors, have basal SK activity that is a consequence of the in-
trinsic catalytic activity of human SK1 (hSK) [5]. This SK
activity can, however, be rapidly increased by various stimuli,
including tumour necrosis factor-K (TNFK) [3,6], phorbol es-
ters [7], platelet-derived growth factor [8], nerve growth factor
[9], N-formyl-methionyl-leucyl-phenylalanine [10], muscarinic
acetylcholine agonists [11], and engagement of the FcORI [12]
and FcQRI [13] antigen receptors. Stimulation of SK activity
by these agonists results in rapid and transient increases in
cellular S1P, the basal levels of which are generally low [14].
This increase in S1P triggers numerous downstream signaling
pathways [1,2] that can be blocked by the presence of SK
inhibitors [6] or a dominant-negative SK we have recently
developed that blocks SK activation [7].
We [5] and others [15,16] have recently cloned hSK. Se-
quence analysis of hSK [5,7] or other recently cloned SKs
[17^20] has provided very little information regarding its
structure, location of the substrate-binding sites, or possible
activation mechanisms. Residues 16 to 153 of hSK have sim-
ilarity to the putative diacylglycerol kinase (DGK) catalytic
domain [7], possessing 17 of the 24 very highly conserved
amino acids of this domain. This includes the residue (Gly82
in hSK) that is known to be essential for catalytic activity in
DGK [21,22], which we have also recently shown to be essen-
tial for the catalytic activity of hSK [7]. However, like SKs,
very little else is known of the structure of DGKs. hSK has
three putative calcium/calmodulin-binding motifs, consistent
with the observation that hSK binds to calmodulin^Sepharose
4B in the presence of calcium [5,23]. However, calcium/cal-
modulin does not appear to modulate the catalytic activity of
hSK in vitro [5]. hSK has no other obvious regulatory do-
mains, with the possible exception of a proline-rich region at
the C-terminus which has resemblance to SH3-binding do-
mains. Furthermore, there is no close similarity to any estab-
lished ATP-binding motifs, or recognisable pockets of hydro-
phobic residues that may be involved in sphingosine binding.
Thus, very little is known of the mechanisms of catalysis or
regulation of hSK.
In this study we have described the mutagenesis of Gly113 of
hSK, a residue highly conserved between the known SKs and
many DGKs [7]. We ¢nd that introduction of a bulky, neg-
atively charged residue at this site (Gly113CAsp) substantially
decreases the activity of the enzyme but that, remarkably,
introduction of a more conservative change (Gly113CAla)
creates an enzyme that exhibits increased activity relative to
the wild-type enzyme.
2. Materials and methods
2.1. Construction and expression of hSK mutants
Wild-type hSK (hSKWT) cDNA [5] (GenBank accession number
AF200328) was FLAG epitope-tagged at the 3P-end and subcloned
into pALTER (Promega, Madison, WI, USA) site-directed mutagen-
esis vector, as previously described [7]. Single-stranded DNA was
prepared and used as a template for oligonucleotide-directed muta-
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genesis as detailed in the manufacturer’s protocol. The mutagenic
oligonucleotides 5P-CCCAGCAGGATCCGACAACGCGCT-3P and
5P-CCCAGCAGGATCCGCCAACGCGCT-3P were designed to gen-
erate the hSKG113D (hSK with Gly113CAsp mutation) and hSKG113A
(hSK with Gly113CAla mutation) mutants, respectively. Both mu-
tants were sequenced to verify incorporation of the desired modi¢ca-
tion. The mutant cDNA were then subcloned into pcDNA3 (Invitro-
gen, San Diego, CA, USA) for transient transfection into HEK293T
cells.
2.2. Cell culture and transfection
Human embryonic kidney cells (HEK293T, ATCC CRL-1573) were
cultured on Dulbecco’s modi¢ed Eagle’s medium (CSL Biosciences,
Parkville, Australia) containing 10% foetal calf serum, 2 mM gluta-
mine, 0.2% (w/v) sodium bicarbonate, penicillin (1.2 mg/ml), and gen-
tamycin (1.6 mg/ml). Transfections were performed using the calcium
phosphate precipitation method [24]. Cells were harvested 24 h after
transfection and lysed by sonication (2 W for 30 s at 4‡C) in lysis
bu¡er containing 50 mM Tris^HCl (pH 7.4), 10% (w/v) glycerol,
0.05% (w/v) Triton X-100, 150 mM NaCl, 1 mM dithiothreitol,
2 mM Na3VO4, 10 mM NaF, 1 mM EDTA and protease inhibitors
(Complete1 ; Boehringer Mannheim). Activation of hSKG113A was
assessed by treatment of cells with either phorbol 12-myristate 13-
acetate (PMA; Sigma) for 30 min, or TNFK (RpD Systems, Minne-
apolis, MN, USA) for 10 min, as previously described [7]. Protein
concentrations in cell homogenates were determined with Coomassie
brilliant blue (Sigma) reagent using bovine serum albumin (BSA) as
standard.
2.3. SK assays
SK activity was routinely determined using D-erythro-sphingosine
(Biomol, Plymouth Meeting, PA, USA) and [Q-32P]ATP (Geneworks,
Adelaide, South Australia) as substrates, as described previously [5].
A unit (U) of SK activity is de¢ned as the amount of enzyme required
to produce 1 pmol S1P/min. Substrate kinetics were analysed using
Michaelis^Menten kinetics with the non-linear regression program,
Hyper 1.1 s. For assays examining substrate presentation, sphingosine
(2 mM) was solubilised in 2% (w/v) BSA in 50 mM Tris^HCl, pH 7.4
by sonication (4 W for 30 s at 4‡C).
2.4. Calmodulin-binding assay for assessing correct folding of SK
mutants
To assess the e¡ect of mutations on gross folding of hSK we have
developed an assay which exploits the known interaction of hSK with
calmodulin, which occurs only with correctly folded hSK protein [5].
HEK293T cells overexpressing hSKWT or mutant hSKs were har-
vested and lysed as described above. The cell lysates were then cen-
trifuged (13 000Ug, 15 min at 4‡C) to remove cell debris. Aliquots of
the supernatants were added to tubes containing calmodulin^Sephar-
ose 4B (Amersham Pharmacia Biotech) pre-equilibrated with binding
bu¡er composed of 50 mM Tris^HCl (pH 7.4), 5 mM CaCl2, 200 mM
NaCl, 10% (w/v) glycerol, 0.05% (w/v) Triton X-100, 1 mM dithio-
threitol, 2 mM Na3VO4, 10 mM NaF and protease inhibitors (Com-
plete1). Further binding bu¡er was then added and the mixtures
incubated for 2 h at 4‡C with continuous mixing. The calmodulin^
Sepharose 4B beads were then pelleted by centrifugation (3500Ug,
5 min at 4‡C) and washed twice with binding bu¡er. hSK bound to the
beads were then resolved by sodium dodecyl sulphate^polyacrylamide
gel eletrophoresis (SDS^PAGE) and visualised by Western blotting
via their FLAG epitope. Binding of the hSKWT and mutant hSKs
to Sepharose CL-4B (Amersham Pharmacia Biotech) was also as-
sessed as a control for non-speci¢c binding to the Sepharose 4B beads.
2.5. Western blotting
SDS^PAGE was performed on cell lysates according to the method
of Laemmli [25] using 12% acrylamide gels. Proteins were blotted to
nitrocellulose and the membranes blocked overnight at 4‡C in PBS
containing 5% skim milk powder and 0.1% (w/v) Triton X-100. hSK
expression levels in cell lysates were quantitated over a dilution series
of the lysates with the monoclonal M2 anti-FLAG antibody (Sigma),
with the immunocomplexes detected with both horseradish peroxidase
(HRP) anti-mouse (Pierce) IgG using an enhanced chemiluminescence
kit (ECL, Amersham Pharmacia Biotech), and alkaline phosphatase
anti-mouse (Selinus/Amrad, Melbourne, Australia) IgG using an ECF
kit (Amersham Pharmacia Biotech) and a Molecular Dynamics (Sun-
nyvale, CA, USA) £uorimager.
3. Results and discussion
3.1. Site-directed mutagenesis of hSK
We have recently cloned and characterised hSK [5]. Our
analysis has shown similarity in residues 16 to 153 of the
hSK amino acid sequence to the putative catalytic domain
of DGKs [7]. Several amino acids are highly conserved in
this region between the known SKs and many DGKs [7].
We have recently reported that mutation of one of these con-
served residues (Gly82CAsp) results in a catalytically inactive
hSK [7]. Another highly conserved residue corresponds to
Gly113 of hSK. This residue, like Gly82 [7], occurs within a
pocket of highly conserved residues rich in glycines (Fig. 1), a
characteristic often associated with loop regions coordinating
nucleotide binding [27,28]. To test the functional importance
of this highly conserved residue, we carried out site-directed
mutagenesis on Gly113 in hSK.
Two mutations were performed to study the importance of
Gly113 in hSK. Initially we generated a disruptive
Gly113CAsp mutation. This mutation increases the size of
Fig. 1. Partial sequence alignment of SKs and some DGKs showing
high sequence conservation around Gly113 of hSK. The sequence
alignment was from the DGK putative catalytic domain family of
the SMART database [26]. Highly conserved residues within this re-
gion are highlighted. The marked (b) residue indicates Gly113 of
hSK [5].
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the residue and introduces a negative charge and is expected
to be maximally disruptive to short-range interactions of the
glycine residue. We then generated a more conservative
Gly113CAla mutation to test whether subtle changes in struc-
ture at this site would a¡ect catalytic activity. Expression of
hSKG113D, hSKG113A and hSKWT in HEK293T cells, followed
by quantitative Western blotting showed that while all three
proteins were present in similar mass levels (Fig. 2B), their SK
activities in the cell lysates varied dramatically (Fig. 2A).
As previously reported [5,7], overexpression of hSKWT pro-
duces high cellular SK activity, with a speci¢c activity of 185
kU/mg protein. This represents an increase in SK activity of
approximately 2000-fold over the low endogenous SK activity
present in these cells. However, expression of similar mass
levels of hSKG113D resulted in only very low levels of SK
activity (Fig. 2A). In fact, hSKG113D showed less than 2% of
the activity of hSKWT, when normalised for protein expres-
sion levels. To assess the e¡ect of this mutation on gross
folding of hSK we exploited the known interaction of hSK
with calmodulin, which occurs only with correctly folded hSK
protein [5]. Like hSKWT, hSKG113D bound speci¢cally to cal-
modulin^Sepharose (Fig. 2C) verifying that the protein was
still folded in the correct manner to allow this interaction to
exist [5]. Therefore, the Gly113CAsp mutation had a pro-
found negative e¡ect on the catalytic activity of hSK, suggest-
ing that Gly113 has an important role in the catalytic mecha-
nism of hSK. Interestingly, while Gly113 is highly conserved in
SKs and many DGKs, an aspartate occurs at the correspond-
ing position in a SK from Arabidopsis thaliana (Fig. 1) [20].
The functional characterisation of this enzyme, however, has
not been reported. Therefore, it is not known if this Arabi-
dopsis SK has low speci¢c activity, or if a divergence in an-
other region of the protein compensates for the presence of
this aspartate.
Surprisingly, expression of hSKG113A, containing the more
conservative Gly113CAla mutation, in HEK293T cells pro-
duced considerably higher SK activity than those transfected
with hSKWT (Fig. 2A). In fact, when normalised for protein
expression levels the Gly113CAla mutation increased catalytic
activity of hSKWT by 1.7-fold under our standard assay con-
ditions. This is a signi¢cant increase in catalytic activity given
that agonist stimulation of hSK in various cell types results in
approximately two-fold increases in SK activity [3,7,12,29].
Substrate kinetic analysis of hSKG113A (Fig. 2D) demon-
strated that the observed increased activity of this mutant
was a consequence of a higher Vmax, rather than altered sub-
strate a⁄nity, since hSKG113A gave comparable Km values for
ATP and sphingosine as hSKWT.
Fig. 2. Site-directed mutagenesis of Gly113 of hSK. A: HEK293T cells transfected with either pcDNA3-hSKWT, pcDNA3-hSKG113A pcDNA3-
hSKG113D or empty pcDNA3 vector were harvested and analysed for SK activity. SK activities given are relative to the activity of hSKWT and
corrected for slight di¡erences in hSK expression levels. B: Expression of the hSKs were quantitated over a dilution range (0.1 to 1 Wg protein)
by Western blot using the anti-FLAG antibody, anti-mouse HRP and ECL reagent. Band densities for hSKWT (b), hSKG113A (a) and
hSKG113D (S) were quantitated using ImageQant software (Molecular Dynamics), showing linearity in the quantitation over this protein con-
centration range with correlation coe⁄cients of 0.991, 0.995 and 0.997 for hSKWT, hSKG113A and hSKG113D, respectively. Quantitation of hSK
expression by Western blot using the anti-FLAG antibody, anti-mouse alkaline phosphatase and ECF reagent gave similar results (data not
shown). C: Selective binding to calmodulin (CaM)^Sepharose indicated that the mutant hSKs were correctly folded. D: Substrate kinetics with
ATP and sphingosine for hSKWT (b) and hSKG113A (a) indicate that the Gly113CAla mutation increases the catalytic e⁄ciency but does not
alter the binding a⁄nity for either substrate. Km values for ATP of hSKWT and hSKG113A were 85 þ 12 and 71 þ 10 WM, respectively, while Km
values for sphingosine were 17 þ 3 and 20 þ 4 WM, respectively. Vmax values for hSKWT and hSKG113A were 215 þ 24 and 327 þ 31 WU/mg lysate
protein, respectively. All data shown are means þ S.D. of triplicate determinations.
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3.2. hSKG113A has the same stability and substrate accessibility
properties as hSKWT
One explanation for increased activity of hSKG113A in cell
lysates is that the Gly113CAla mutation may have conferred
increased stability of the protein. Previously, GlyCAla muta-
tions have been reported to increase the stability of lysozyme
and some other proteins by decreasing the entropy of unfold-
ing [30]. To test this we examined the thermostability of both
hSKWT and hSKG113A. The results (Fig. 3A) show that both
enzymes have almost identical thermostabilities. This indicates
that the observed higher activity of hSKG113A is not a conse-
quence of enhanced protein stability over hSKWT.
Next, we considered the possibility that the Gly113CAla
mutation may have enhanced the ability of hSKG113A to ac-
cess sphingosine in our in vitro enzyme assays. Unlike en-
zymes that act on soluble substrates, our standard SK assays
rely on supplying sphingosine as a mixed micelle with Triton
X-100. This means that the SK must interact with the Triton
X-100 micelle to gain access to sphingosine, in a comparable
manner to how it most likely encounters this substrate in vivo
in various cellular membranes [31]. Therefore, a mutation that
alters the dynamics of this interaction may alter the observed
catalytic e⁄ciency of an enzyme. To test this, we examined the
activity of hSKWT and hSKG113A with sphingosine supplied as
a BSA-solubilised complex, a widely used alternative sub-
strate-delivery system [32]. The results (Fig. 3B) show that,
while the BSA-solubilised sphingosine supported much lower
activity than with the mixed micelle assay, hSKG113A still dis-
played approximately 1.7-fold higher activity than hSKWT
under these conditions. This suggests that the increased activ-
ity shown by hSKG113A is not a consequence of the substrate
presentation conditions, but is truly an increase in catalytic
e⁄ciency.
3.3. The Gly113CAla mutation does not mimic
agonist-dependent hSK activation
The fold increase in SK activity induced by the
Gly113CAla mutation (1.7-fold) is remarkably similar to the
increase in SK activity observed upon treatment of cells with
agonists like TNFK or PMA (1.5- to 2-fold) [5^7]. Further-
more, like hSKG113A (Fig. 2D), this increase in SK activity
observed during agonist-mediated activation arises from an
increase in Vmax of the enzyme [33]. Thus, we considered the
possibility that the Gly113CAla mutation may have induced a
conformational change in hSK towards the, as yet unidenti-
¢ed, activated form of this enzyme. To investigate this, we
examined the activation of SK activity in hSKG113A- and
hSKWT-transfected HEK293T cells in response to TNFK
and PMA (Fig. 4). As reported previously [5,7], hSKWT ac-
tivity was stimulated almost two-fold by these agonists.
hSKG113A activity was stimulated by these agonists to the
same degree as hSKWT (Fig. 4). If the Gly113CAla mutation
mimicked the agonist-induced activation we would not have
expected any stimulatory e¡ect of these agonists on hSKG113A
activity. Our observations suggest that the structural change
in hSK created by the Gly113CAla mutation that enhances
SK activity is not directly related to conformational changes
that increase SK activity during hSK activation.
3.4. Conclusions
Here we have probed the role of Gly113, a residue highly
conserved among SKs and DGKs. To accomplish this we
have utilised two mutations, one disruptive and one relatively
subtle. The disruptive mutation, Gly113CAsp markedly de-
creased catalytic activity. Surprisingly the more conservative
Gly113CAla mutation resulted in a hSK mutant (hSKG113A)
that has 1.7-fold greater catalytic activity than hSKWT. This,
together with the very low activity of the hSKG113D mutant
indicates Gly113 has an important role in the catalytic mech-
anism of hSK. We have previously reported the generation of
a catalytically inactive mutant of hSK through mutagenesis of
Gly82CAsp [7]. This Gly82CAsp mutation interferes with
Fig. 3. The increased catalytic activity of hSKG113A is not a result
of enhanced stability or substrate accessibility. A: To determine the
thermal stability of hSKWT or hSKG113A lysates from HEK293T
cells transfected with either hSKWT (b) or hSKG113A (a) were di-
luted in lysis bu¡er, incubated at the indicated temperatures for 30
min, and then assayed for residual SK activity. B: To determine the
e¡ect of substrate presentation on the activity of hSKWT and
hSKG113A lysates from HEK293T cells transfected with either
hSKWT (¢lled bars) or hSKG113A (open bars) were assayed using
sphingosine (100 WM) supplied in Triton X-100 (0.25% w/v ¢nal Tri-
ton X-100 concentration) mixed micelles or as a BSA complex
(0.1% w/v ¢nal BSA concentration). In all cases SK activities are
expressed relative to the protein concentrations of cell lysates and
are means þ S.D. of triplicate determinations from three independent
experiments.
Fig. 4. Activation of hSKWT and hSKG113A by TNFK and PMA.
HEK293T cells transfected with either hSKWT or hSKG113A were
harvested and assayed for SK activity after treatment with either
1 ng/ml TNFK for 10 min or 100 ng/ml PMA for 30 min. SK activ-
ities are expressed relative to protein concentrations of cell lysates
and are means þ S.D. of triplicate determinations from three inde-
pendent experiments.
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ATP binding (our unpublished observations). This is consis-
tent with the loose similarity between this region and the gly-
cine-rich loop within the ATP-binding site of protein kinases
[27]. The current study has shown a further conserved region
around Gly113 is also important in the catalytic activity of
hSK. However, unlike Gly82, it appears that Gly113 is not
directly involved in substrate binding since hSKG113A showed
similar a⁄nity for ATP and sphingosine as hSKWT. Instead,
our data suggests that the Gly113CAla mutation increases
catalytic e⁄ciency of hSK.
SKs and DGKs represent a novel class of lipid kinases, one
for which no structural information has been attained, and
where the mechanism of phosphoryl transfer is unknown. The
Gly113CAla in hSK increases the e⁄ciency of this transfer
without altering the substrate-binding kinetics of this enzyme.
This indicates that this mutation may induce a conformational
change that increases the e⁄ciency of phosphoryl transfer.
Importantly, we have shown that hSKG113A can still be acti-
vated by cell agonists indicating that the structural change in
hSK created by this mutation is not related to any conforma-
tional change that may arise during the currently unknown
hSK activation mechanism. Ongoing structural and mutagenic
studies are aimed at determining the structural basis of catal-
ysis of this novel class of kinases and how Gly113CAla in-
duces a hyper-active conformation.
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